CaltechAUTHORS
  A Caltech Library Service

A prudent path forward for genomic engineering and germline gene modification

Baltimore, David and Berg, Paul and Botchan, Michael and Carroll, Dana and Alto Charo, R. and Church, George and Corn, Jacob E. and Daley, George Q. and Doudna, Jennifer A. and Fenner, Marsha and Greely, Henry T. and Jinek, Martin and Martin, G. Steven and Penhoet, Edward and Puck, Jennifer and Sternberg, Samuel H. and Weissman, Jonathan S. and Yamamoto, Keith R. (2015) A prudent path forward for genomic engineering and germline gene modification. Science, 348 (6230). pp. 36-38. ISSN 0036-8075. PMCID PMC4394183. https://resolver.caltech.edu/CaltechAUTHORS:20150319-185722928

[img] PDF - Accepted Version
See Usage Policy.

55Kb

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20150319-185722928

Abstract

A framework for open discourse on the use of CRISPR-Cas9 technology to manipulate the human genome is urgently needed.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://dx.doi.org/10.1126/science.aab1028 DOIArticle
http://www.sciencemag.org/content/348/6230/36PublisherArticle
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394183PubMed CentralArticle
ORCID:
AuthorORCID
Baltimore, David0000-0001-8723-8190
Additional Information:© 2015 American Association for the Advancement of Science. Published online March 19 2015. J.A.D. and M.J. are cofounders of Caribou Biosciences, Inc., which develops CRISPR-Cas technology for genome engineering for agricultural and biomedical applications. J.A.D. and M.J. are on the Scientific Advisory Board of Caribou Biosciences, Inc. G.C. has been an advisor to Caribou Biosciences, Inc. G.C. and J.A.D. are cofounders of, and G.C. is a member of the Scientific Advisory Board of, Editas Medicine, a company that translates genome editing technology into human therapeutics. G.C. has been an advisor to Sigma-Aldrich, which sells products related to CRISPR-Cas technology. D.C. is on the Scientific Advisory Board of Recombinetics, Inc., which develops genome engineering approaches for agricultural and biomedical applications. E.P. is director of Alta Partners, Ltd., a shareholder in Kite Pharmaceuticals, which develops genome engineering for biomedical applications. G.C. is an inventor on patents filed by Harvard University that cover the use of Cas9 in human cells, and reduction in off-target activity. J.A.D. is an inventor on patents filed by the University of California for research and development on CRISPR-Cas9–mediated genome engineering. J.S.W. is an inventor on patents filed by the University of California, San Francisco, the University of California, Berkeley, and the Howard Hughes Medical Institute, that cover CRISPR screening technology.
Issue or Number:6230
PubMed Central ID:PMC4394183
Record Number:CaltechAUTHORS:20150319-185722928
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20150319-185722928
Official Citation:A prudent path forward for genomic engineering and germline gene modification David Baltimore, Paul Berg, Michael Botchan, Dana Carroll, R. Alta Charo, George Church, Jacob E. Corn, George Q. Daley, Jennifer A. Doudna, Marsha Fenner, Henry T. Greely, Martin Jinek, G. Steven Martin, Edward Penhoet, Jennifer Puck, Samuel H. Sternberg, Jonathan S. Weissman, and Keith R. Yamamoto Science 3 April 2015: 348 (6230), 36-38.Published online 19 March 2015 [DOI:10.1126/science.aab1028]
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:55938
Collection:CaltechAUTHORS
Deposited By: Joy Painter
Deposited On:20 Mar 2015 02:36
Last Modified:03 Oct 2019 08:10

Repository Staff Only: item control page